OPTIONS FOR H1N1

 

OPTION 1. MAINTAIN CURRENT VACCINE STRAIN,

A/NEW CALEDONIA/20/99

 

 

PRO MANUFACTURING IS WORKED OUT AND

YIELD IS PREDICTABLE

MOST OF THE VIRUSES THIS YEAR ARE

A/NEW CALEDONIA/20/99-LIKE BY ANTIGENIC CHARACTERIZATION OF THE HEMAGLUTININ

 

CON RELATIVELY FEW RECENT STRAINS FOR ANALYSIS

 

OPTIONS FOR H1N1

 

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO A STRAIN MORE REPRESENTATIVE OF CURRENTLY CIRCULATING VIRUSES

 

 

PRO A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

 

 

CON A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN

NO NEW STRAINS HAVE BEEN IDENTIFIED AND MANUFACTURING ISSUES HAVE NOT BEEN INVESTIGATED

OPTIONS FOR H1N1

 

OPTION 3. POSTPONE DECISION

 

 

PRO A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

 

 

CON NO NEW DATA APPEARS FORTHCOMING

 

 

 

OPTIONS FOR H3N2

 

OPTION 1. MAINTAIN CURRENT VACCINE STRAIN, A/PANAMA/2007/99

 

 

PRO MANUFACTURING IS WORKED OUT AND

YIELD IS PREDICTABLE

MOST OF THE VIRUSES THIS YEAR ARE A/PANAMA/2007/99-LIKE BY ANTIGENIC CHARACTERIZATION OF THE HEMAGLUTININ

 

CON INFORMATION ABOUT NEWEST STRAINS IS NOT YET ANALYZED

H3N2 INFLUENZA VIRUSES ARE OFTEN RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND MORTALITY

 

OPTIONS FOR H3N2

 

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO A STRAIN MORE REPRESENTATIVE OF CURRENTLY CIRCULATING VIRUSES

 

 

PRO A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

H3N2 INFLUENZA VIRUSES OFTEN RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND MORTALITY

 

CON INFORMATION ABOUT NEWEST STRAINS IS NOT YET ANALYZED

A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN

NO NEW STRAINS HAVE BEEN EVALUATED FOR MANUFACTURING ISSUES

OPTIONS FOR H3N2

 

OPTION 3. POSTPONE DECISION

 

 

PRO POSTPONING DECISION WOULD PROVIDE TIME TO ANALYZE NEWLY COLLECTED STRAINS

A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

H3N2 INFLUENZA VIRUSES OFTEN RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND MORTALITY

 

CON A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN

NO NEW STRAINS HAVE BEEN IDENTIFIED AND MANUFACTURING ISSUES HAVE NOT BEEN INVESTIGATED

OPTIONS FOR B

 

OPTION 1. RETAIN THE CURRENT VACCINE STRAINS,

B/VICTORIA/504/2000 OR B/GUANGDONG/120/2000

 

PRO MANUFACTURING IS WELL DEFINED AND

PREDICTABLE

 

CON SOME NEW VARIANT STRAINS HAVE BEEN IDENTIFIED IN THE VACCINE HA LINEAGE

STRAINS IN THE B/SHANGDONG/7/97 HA LINEAGE ARE APPEARING IN INCREASING NUMBERS AND IN NEW REGIONS

SOME INFLUENZA B STRAINS, PARTICULARLY THOSE IN THE B/SHANGDONG/7/97 HA LINEAGE, ARE NOT WELL INHIBITED BY POST-INFECTION AND POST-IMMUNIZATION ANTISERA

 

 

OPTIONS FOR B

 

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO ANOTHER INFLUENZA B STRAIN

 

PRO VACCINES MIGHT PROVIDE BROADER COVERAGE FOR CURRENT INFLUENZA B VIRUSES

SEVERAL CANDIDATE STRAINS HAVE BEEN IDENTIFIED AND ARE BEING EXAMINED FOR SUITABILITY BY MULTIPLE MANUFACTURERS

 

CON NEW STRAINS MAY CAUSE DIFFICULTIES IN MANUFACTURING UNTIL ALL PROCESS PARAMETERS CAN BE OPTIMIZED

 

 

OPTIONS FOR B

 

OPTION 3. POSTPONE DECISION

 

 

PRO POSTPONING DECISION WOULD PROVIDE TIME TO FOR ADDITIONAL EVALUATIONS OF INFLUENZA B STRAINS

A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

 

 

CON A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN